The role of the gut microbiota in understanding functional gastrointestinal disorders
DOI:
https://doi.org/10.12775/JEHS.2023.30.01.009Keywords
functional disorders, irritable bowel syndrome, gastrointestinal, fecal microbiota dysbiosisAbstract
One of the most prevalent digestive diseases worldwide, functional gastrointestinal dysfunction (FGID) places a substantial strain on healthcare resources and causes significant morbidity. A study using Rome IV diagnostic criteria estimates the prevalence of FGID is about 40% worldwide. Most people with FGID exhibit symptoms from the realm of psychopathology, most often anxiety and depression, making patients' quality of life lower compared to even those with chronic organic diseases. By elucidating the causes and consequences of qualitative and quantitative changes between the microbiota of a healthy person and the microbiota of a person with FDIG, incredible progress has been made in understanding the role of the gut microbiota in FGID. However, the exact cellular and molecular pathogens of FGID that are directed by the gut microbiota remain unknown, and learning more about them will result in non-empirical, but targeted therapies.
References
Aro P, Talley NJ, Ronkainen J, et al. Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study. Gastroenterology. 2009;137:94–100.
Aziz I, Palsson OS, Tornblom H, et al. The prevalence and impact of overlapping rome iv-diagnosed functional gastrointestinal disorders on somatization, quality of life, and healthcare utilization: a cross-sectional general population study in three countries. Am J Gastroenterol 2018;113:86–96.
Barbara G, Feinle‐Bisset C, Ghoshal UCet al. The intestinal microenvironment and functional gastrointestinal disorders. Gastroenterology. 2016; 150: 1305–1318.e8.
Camilleri M, Oduyebo I, Halawi H. Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unanswered questions. Am. J. Physiol. Gastrointest. Liver Physiol. 2016; 311: G777–84.
Dalile B, Van Oudenhove L, Vervliet Bet al. The role of short‐chain fatty acids in microbiota‐gut‐brain communication. Nat. Rev. Gastroenterol. Hepatol. 2019; 16: 461–78.
De Palma G, Collins SM, Bercik P. The microbiota-gut-brain axis in functional gastrointestinal disorders. Gut Microbes. 2014 May-Jun;5(3):419-29. doi: 10.4161/gmic.29417. Epub 2014 Jun 12. PMID: 24921926; PMCID: PMC4153782.
De Vadder F, Grasset E, Manneras Holm Let al. Gut microbiota regulates maturation of the adult enteric nervous system via enteric serotonin networks. Proc. Natl. Acad. Sci. U.S.A. 2018; 115: 6458–63.
El‐Salhy M, Hatlebakk JG, Gilja OHet al. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double‐blind, placebo‐controlled study. Gut. 2020; 69: 859–67.
Fikree A, Byrne P. Management of functional gastrointestinal disorders. Clin Med (Lond). 2021 Jan;21(1):44-52. doi: 10.7861/clinmed.2020-0980. PMID: 33479067; PMCID: PMC7850201.
Fung TC, Vuong HE, Luna CDGet al. Intestinal serotonin and fluoxetine exposure modulate bacterial colonization in the gut. Nat. Microbiol. 2019; 4: 2064–73.
Ge X, Zhao W, Ding Cet al. Potential role of fecal microbiota from patients with slow transit constipation in the regulation of gastrointestinal motility. Sci. Rep. 2017; 7: 441.
Ghoshal UC, Singh R. Frequency and risk factors of functional gastro‐intestinal disorders in a rural Indian population. J. Gastroenterol. Hepatol. 2017; 32: 378–87.
Guthrie E, Creed F, Fernandes L, et al. Cluster analysis of symptoms and health seeking behaviour differentiates subgroups of patients with severe irritable bowel syndrome. Gut. 2003;52:1616–1622.
Hegyi P, Maleth J, Walters JRet al. Guts and gall: bile acids in regulation of intestinal epithelial function in health and disease. Physiol. Rev. 2018; 98: 1983–2023.
Lee S, Wu J, Ma YL, Tsang A, Guo WJ, Sung J. Irritable bowel syndrome is strongly associated with generalized anxiety disorder: a community study. Aliment Pharmacol Ther. 2009;30:643–651.
Low K, Hwang L, Hua J, Zhu A, Morales W, Pimentel M. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J. Clin. Gastroenterol. 2010; 44: 547–50.
Petersen MW, Schroder A, Jorgensen T, et al. Irritable bowel, chronic widespread pain, chronic fatigue and related syndromes are prevalent and highly overlapping in the general population: DanFunD. Sci Rep 2020;10:3273.
Pimentel M, Chatterjee S, Chow EJ, Park S, Kong Y. Neomycin improves constipation‐predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double‐blind randomized controlled study. Dig. Dis. Sci. 2006; 51: 1297–301.
Priyadarshini M, Kotlo KU, Dudeja PK, Layden BT. Role of short chain fatty acid receptors in intestinal physiology and pathophysiology. Compr. Physiol. 2018; 8: 1091–115.
Pulipati P, Sarkar P, Jakkampudi Aet al. The Indian gut microbiota‐Is it unique? Indian J. Gastroenterol. 2020; 39: 133–40.
Reigstad CS, Salmonson CE, Rainey JF 3rdet al. Gut microbes promote colonic serotonin production through an effect of short‐chain fatty acids on enterochromaffin cells. FASEB J. 2015; 29: 1395–403.
Shanahan F, Ghosh TS, O'Toole PW. The healthy microbiome‐what is the definition of a healthy gut microbiome? Gastroenterology. 2021; 160: 483–94.
Sperber AD, Bangdiwala SI, Drossman DAet al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 2021; 160: 99–114 e3.
Spiegel B, Harris L, Lucak S, et al. Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort. Am J Gastroenterol 2009;104:1984–91.
Sun Q, Jia Q, Song L, Duan L. Alterations in fecal short‐chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta‐analysis. Medicine (Baltimore). 2019; 98: e14513.
Tan V. P., Liu K. S., Lam F. Y., Hung I. F., Yuen M. F., Leung W. K. (2017). Randomised Clinical Trial: Rifaximin versus Placebo for the Treatment of Functional Dyspepsia. Aliment. Pharmacol. Ther. 45 (6), 767–776. 10.1111/apt.13945
Walters JR, Pattni SS. Managing bile acid diarrhoea. Therap Adv Gastroenterol 2010;3:349–57.
Wedlake L, A'Hern R, Russell Det al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea‐predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 2009; 30: 707–17.
Wei L, Singh R, Ro S, Ghoshal UC. Gut microbiota dysbiosis in functional gastrointestinal disorders: Underpinning the symptoms and pathophysiology. JGH Open. 2021 Mar 23;5(9):976-987. doi: 10.1002/jgh3.12528. PMID: 34584964; PMCID: PMC8454481.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Witold Zardzewiały, Radosław Bernacki, Piotr Bernacki, Oleksii Zaremskyi, Martyna Dutka, Dominik Szawica, Aleksandra Kuźniar, Michał Oleszko, Edward Wąsiewicz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 247
Number of citations: 0
